Beximco Pharma Discussion Threads

[deltrotter] 27/1/2017 09:07

Excellent results from a super little company. What a lot of growth prospects they have. Well done them, and great for the Bangladeshi people.

[someuwin] 27/1/2017 08:08

Moving up.

[someuwin] 27/1/2017 07:19

BEXIMCO PHARMACEUTICALS LTD.

27 January, 2017

Half Year Results 2016-17

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its un-audited financial results for the six months ended 31 December, 2016.

Financial highlights

Half year financial highlights

-- Net sales increased by 13.6% to Bangladesh Taka ("BDT") 7,630.6 m / GBP79.7 m (2015: BDT 6,716.3m / GBP58.0m)

-- Profit after tax increased by 17.8% to BDT 1,112.9m / GBP11.6m (H1 2015: BDT 945.1m/ GBP8.2m)

Second quarter financial highlights

-- Net sales increased 16.0% to BDT 3,865.0m / GBP40.4m (2015: BDT 3,330.6m / GBP28.8m)
-- Profit after tax increased 14.0 % to BDT 598.0m / GBP6.2m (2015: BDT 524.5 m / GBP4.5m)

Operational highlights

-- A total of eight new products (five generics) launched in the domestic market

o Three of which were launched for the first time in Bangladesh (Voglibose, Cholecalciferol and Dienogest)

-- Commenced US export of Carvedilol, a prescription drug for treating hypertension, in August

o The first Bangladeshi pharmaceutical company to export pharmaceutical products to the US

-- Received approval for two more products, Sotalol and Metformin Hydrochloride, from US FDA in November and December, respectively

-- Medicine Patent Pool (MPP) of the UN granted sub-license to Beximco Pharma to manufacture Bristol-Myers Squibb's new hepatitis C drug, Daclatasvir

-- Received product approval from Health Canada for Olopatadine eye drop

o Another first time achievement for a Bangladeshi pharmaceutical company

-- Two ophthalmic products registered in Australia
-- Commenced export to Panama, Zimbabwe, Mali and Guinea

Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented:

"With the formal launch of Carvedilol in August, Beximco Pharma became the first Bangladeshi pharmaceutical company to export a prescription drug to US. In addition, we received approval for two more products from US FDA during the period. We continued to perform well in the domestic market, posting a sales growth of 14.4% over the corresponding period in 2015. We are confident that we will be able to maintain our growth momentum by achieving our operational and financial targets for the full year."

[firtashia] 26/1/2017 12:30

someuwin (post 77)- I echo your sentiments. The FDA have recently been revoking the licence of many Indian pharmaceutical companies to sell generics/API in the US, you would imagine this trend to continue under Trump. For Beximco to actually receive approval of 3 of their products during this period is certainly swimming against the tide and does indeed tell you something about the quality of their business.

[greg the grinch] 26/1/2017 11:18

:o)

That's the spike I have been waiting for.... it has more to go... :o)

I am holding for years as this will multibag.

GLA

[someuwin] 26/1/2017 10:50

Irrespective of actual sales to the US (which I believe will ramp up quickly), the game changer here is the fact that they have received FDA approval for not just one, but three seperate drugs: Blood pressure, cardiovascular and diabetes. (all approvals granted in the last 12 months).

Its a great testament to their design and production quality. And will aid sales of all their products worldwide.

[jswjsw] 26/1/2017 10:33

Actually the US products only account for a very small part of revenue. What Trump does doesn't really make much difference to them, especially since they are doing so well in the Far East.
59p UK against 91.1p Dhaka equivalent is ridiculous.
j

[deltrotter] 26/1/2017 09:18

Bit of a spike:



;-)

[deltrotter] 26/1/2017 08:39

Closed at 91p in Dhaka

[deltrotter] 26/1/2017 08:24

On the back of big volume as well - hope it is not an approach.

[deltrotter] 26/1/2017 08:13

Have their results been published over there or something????

[deltrotter] 26/1/2017 08:08

Crikey - breaking out now in Dhaka

[mustau] 25/1/2017 15:36

Looking at trades, seems most are buys today.

[deltrotter] 25/1/2017 15:32

Nice 100k buy ahead of results....

[deltrotter] 25/1/2017 10:12

Totally agree someuwin.

Can anyone with historical knowledge let me know what happened? A change of management 2-3 years ago?

They certainly seem to have developed a cracking company - new export markets, FDA approval (a REAL sign of quality) and now a JV in another country.

Cheers

Ray

[someuwin] 25/1/2017 10:09

Expanding global presence with more and more export routes. And now overseas manufacturing collaborations.

This company is on a very low rating and is set to grow and grow over the coming years. Perfect.

[deltrotter] 25/1/2017 10:05

Dhaka exchange price updated in header - highest close since last March.

I am hoping for a nice increase in the profit/turnover in the interims over the next couple of days and a little divi to boot.

[deltrotter] 25/1/2017 07:50

Really good news that for long term holders. This is proving to be a cracking growth company.

Interims in the next 5 trading days and what looks to be a chart breakout over in Dhaka....

[someuwin] 25/1/2017 07:06

25 January, 2017





BEXIMCO PHARMACEUTICALS LTD.



Beximco Pharma forms JV with Malaysia-based BioCare Manufacturing





Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture ("JV") with BioCare Manufacturing (M) Sdn Bhd ("BioCare") based in Malaysia, as the Company's first overseas manufacturing collaboration.



Under the terms of the JV, Beximco Pharma will provide full technical support to BioCare for the establishment of manufacturing facilities in Seri Iskandar Pharmaceutical Park, Perak, Malaysia to produce specialised pharmaceutical products. Beximco will be issued 30% of the equity shares in the JV company. BioCare will operate and fund the facility.



In the first phase of the project, an international standard metered dose inhaler facility has been created which has already received good manufacturing practices ("GMP") approval from Ministry of Health ("MoH") Malaysia.



Whilst it is expected that the JV's first sales from this facility will be made during 2017, the Company does not expect a significant contribution to its profits from the collaboration in the short term. However, the JV is an important testimony of the Company's technical capability as a generic drug manufacturer.



The JV is intended to manufacture and supply differentiated medical products, such as inhalers, under the Malaysian government's Economic Transformation Program. The Malaysian government's initiatives are aimed at increasing investment in the country's pharmaceutical industry to provide dedicated drug manufacturing facilities, improve generic drug capabilities, and promote local production to qualify for government procurement.



BioCare Group (M) Sdn Bhd, the majority shareholder of BioCare, has a strong presence in a range of key therapeutic segments in both government and private healthcare sectors in Malaysia.



Managing Director of Beximco Pharma, Mr. Nazmul Hassan MP, commented:

"This is our first overseas manufacturing collaboration and I believe our JV with BioCare will help address the unmet needs of patients and physicians by supporting the Malaysian government's initiative to promote the local pharmaceutical industry. This kind of collaboration is also in line with our aspiration to continue to strengthen our global presence as a generic pharmaceutical company."

[greg the grinch] 18/1/2017 10:04

The big gains are going to be made 'sittin and waitin'.... if BXP can repeat the latest US drug approval for two or three other generic drugs in the next couple of years and the market can see that cash coming in then we should multibag big time.

:)

[someuwin] 18/1/2017 09:52

Yup - this should soon be attacking new highs.

[deltrotter] 18/1/2017 09:52

Absolutely agreed greg. I think this is a massively different company from 2 years ago, and the market hasnt fully cottoned on yet.

[greg the grinch] 18/1/2017 09:49

I think those sales would only have trickled in so far BUT it will become a flood and that will push the share price up in a big way.. :)

[greg the grinch] 18/1/2017 09:46

Other generic cos are on much higher pe's